FDA Accepts Supplemental NDA for Desmopressin Acetate by Ferring Pharmaceuticals
The FDA has accepted a supplemental NDA for Desmopressin Acetate submitted by Ferring Pharmaceuticals.
Company
Pharmaceutical intelligence for Ferring Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.